German scientists used generative AI to design Synthetic Transfer Vehicles, protein shells that carried RNA into cells more efficiently than the lipid nanoparticles they tested and delivered a CRISPR edit in a pig.
The first blinded, wet-lab-validated benchmark for AI antibody design just landed in Nature Biotechnology. Here is what the models got right, and wrong.
Genentech validated the first AI-discovered neuroscience drug target from its $12B Recursion partnership. A proof point the AI-drug discovery field needed.
Jennifer Doudna's lab used an AI protein-design model to build a synthetic gene-editing enzyme, SynTnpB, that edits human cells nearly twice as efficiently as the natural version. Here is what the Science paper actually shows, and what it does not.
